Informing the pharmaceutical drug development, manufacturing and commercialization industry Cary, NC – March 15, 2016 – Industry Standard Research (ISR) today announced the release of its annual CRO Quality Benchmarking series of reports. These three reports outline in detail the delivery quality of dozens of large, mid-size, and niche CROs for Phase I, Phase II/III and Phase IV clinical services. “As the use of contract research services continues to mature, it is increasingly important for sponsor organizations to make informed purchase decisions,” said Kevin Olson, CEO of Industry Standard Research. “And making informed purchase decisions means evaluating potential CRO partners holistically. Of course a sponsor needs to canvas their internal development organizations for previous experiences with CROs. That is a critical step in the process. But that will represent only a narrow set of experiences with service providers. Our Quality Benchmarking reports give sponsors access to hundreds of additional service provider experiences that will increase the chances of building successful relationships with CRO partners.” These reports provide a Consumer Reports-style analysis where each of the dozens of CROs included in the research was evaluated across 26 service quality attributes, making these reports the most comprehensive assessment of quality in the contract research space. These 26 attributes were categorized into five ‘scorecards’: Delivery Factors, Organization Factors, Budget Factors, Staff Characteristics, and Timelines Management. Respondents were asked to recall their specific experiences working with the service providers, and to indicate how well the CROs performed, relative to the respondent’s expectations. For buyers of outsourced development services, the report includes highly valuable information to help guide selection for Phase I, Phase II/III, and Phase IV development services. For contract service providers, these reports offer a wealth of information to guide operational, marketing, and competitive strategy. The reports include data on 64 different contract research organizations, including: Accell, Accelovance, Accenture, Algorithme Pharma, BioClinica, Bioskin, Biotrial, CEBIS International, Celerion, CHDR, Chiltern, Clinical Research Services (CRS), Clinipace, Clinlogix, Clinsys, Cognizant, Covance, DaVita Clinical Research, DCRI – Duke, Encorium, Eurofins, Eurotrials, Frontage, HungaroTrial, ICON, Inamed, INC Research, inVentiv Health Clinical, KCR, Lambda, Mapi, Medpace, Medsource, NAMSA, Novotech, Novum, Nuvisan, PAREXEL, Pharm-Olam International, PPD, PRA, Premier Research, ProTrials, QPS, Quintiles, Quotient Clinical, Radiant, Rho, SanaClis, Sannova Analytical, SGS Life Sciences, Siro Clinpharm, Southern Star, Spaulding Clinical, Symbio, SynteractHCR, Tata, Theorem, TKL Research, UBC, US Oncology, Vince & Associates, WCCT Global, Worldwide Clinical Trials. For more information on ISR’s CRO Quality Benchmarking reports, please visit our Service Provider Quality Benchmarking Reports category. About Industry Standard Research Industry Standard Research is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience, ISR delivers an unmatched level of domain expertise. For more information about ISR’s off-the-shelf intelligence and custom research offerings, please visit the company’s website at www.isrreports.com, email firstname.lastname@example.org or follow ISR on Twitter @ISRreports.